Beyond utilitarianism: A method for analyzing competing ethical principles in a decision analysis of liver transplantation

Medical Decision Making

Volumn 28, Issue 5, 2008, Pages 763-772

  Volk, Michael L ^a,b,c   Lok, Anna S F ^a   Ubel, Peter A ^a,b   Vijan, Sandeep ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Acute liver failure; Decision support techniques; Ethical theory; Liver transplantation

Indexed keywords

ARTICLE; ETHICAL DECISION MAKING; HOSPITAL ADMISSION; LIVER FAILURE; LIVER TRANSPLANTATION; MORTALITY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS; SURVIVAL;

ACUTE DISEASE; DECISION SUPPORT TECHNIQUES; HUMANS; LIVER TRANSPLANTATION; MARKOV CHAINS; SURVIVAL ANALYSIS; TISSUE AND ORGAN PROCUREMENT; WAITING LISTS;

EID: 52149099048     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X08316999     Document Type: Article

References (41)

1. Freeman RB, Edwards EB, Harper AM Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant. 2006 ; 6: 1416-21.
2. Merion RM When is a patient too well and when is a patient too sick for a liver transplant ? Liver Transpl. 2004 ; 10: S69-73.
3. Barshes NR, Lee TC, Balkrishnan R., Karpen SJ, Carter BA, Goss JA Risk stratification of adult patients undergoing orthotopic liver transplantation for fulminant hepatic failure. Transplantation. 2006 ; 81: 195-201.
4. Desai NM, Mange KC, Crawford MD, et al. Predicting outcome after liver transplantation: utility of the model for end-stage liver disease and a newly derived discrimination function. Transplantation. 2004 ; 77: 99-106.
5. Llovet JM Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data. Liver Transpl. 2006 ; 12: 1741-3.
6. Ubel PA, Nord E., Gold M., Menzel P., Prades JL, Richardson J. Improving value measurement in cost-effectiveness analysis. Med Care. 2000 ; 38: 892-901.
7. Berger ML, Teutsch S. Cost-effectiveness analysis: from science to application. Med Care. 2005 ; 43: 49-53.
8. Strong C. The limited utility of utilitarian analysis. Am J Bioeth. 2006 ; 6: 67-69.
9. Hadorn DC Setting health care priorities in Oregon: cost-effectiveness meets the rule of rescue. JAMA. 1991 ; 265: 2218-25.
10. Rhodes R., Battin MP, Silvers A. Medicine and Social Justice: Essays on the Distribution of Health Care. Oxford (UK): Oxford University Press ; 2002.
11. Gray DE Decision support and moral sensitivity: must one come at the expense of the other ? Am J Bioeth. 2006 ; 6: 59-62.
12. Ubel PA, Hirth RA, Chernew ME, Fendrick AM What is the price of life and why doesn't it increase at the rate of inflation ? Arch Intern Med. 2003 ; 163: 1637-41.
13. Smith CM, Davies DB, McBride MA Liver transplantation in the United States: a report from the Organ Procurement and Transplantation Network. Clin Transpl. 2000: 19-30.
14. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA The survival benefit of liver transplantation. Am J Transplant. 2005 ; 5: 307-13.
15. Ubel PA, Loewenstein G. Distributing scarce livers: the moral reasoning of the general public. Soc Sci Med. 1996 ; 42: 1049-55.
16. Ubel PA, DeKay M., Baron J., Asch DA Public preferences for efficiency and racial equity in kidney transplant allocation decisions. Transplant Proc. 1996 ; 28: 2997-3002.
17. Ratcliffe J. Public preferences for the allocation of donor liver grafts for transplantation. Health Econ. 2000 ; 9: 137-48.
18. United Network for Organ Sharing. Policy 3.6, Organ Distribution: Allocation of Livers. Richmond (VA): United Network for Organ Sharing ; 2006.
19. Amin MG, Wolf MP, TenBrook JA Jr, et al. Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: a decision analysis. Liver Transpl. 2004 ; 10: 1468-75.
20. Roberts JP, Dykstra DM, Goodrich NP, Rush SH, Merion RM, Port FK Geographic differences in event rates by model for end-stage liver disease score. Am J Transplant. 2006 ; 6: 2470-5.
21. Rodriguez-Luna H., Vargas HE, Moss A., Reddy KS, Freeman RB, Mulligan D. Regional variations in peer reviewed liver allocation under the MELD system. Am J Transplant. 2005 ; 5: 2244-7.
22. Gold MR Cost-effectiveness in health and medicine. New York: Oxford University Press ; 1996.
23. Merion RM 2006 SRTR report on the state of transplantation. Am J Transplant. 2007; 7 (Suppl 1). 1317-8.
24. Cheng SJ, Pratt DS, Freeman RB Jr, Kaplan MM, Wong JB Living-donor versus cadaveric liver transplantation for nonresectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation. 2001 ; 72: 861-8.
25. Sharma P., Balan V., Hernandez JL, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl. 2004 ; 10: 36-41.
26. Llovet JM, Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999 ; 29: 62-7.
27. Longworth L., Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 2003 ; 12: 1061-7.
28. Ratcliffe J., Longworth L., Young T., Bryan S., Burroughs A., Buxton M. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl. 2002 ; 8: 263-70.
29. Bryce CL, Angus DC, Switala J., Roberts MS, Tsevat J. Health status versus utilities of patients with end-stage liver disease. Qual Life Res. 2004 ; 13: 773-82.
30. Miyake Y., Sakaguchi K., Iwasaki Y., et al. New prognostic scoring model for liver transplantation in patients with non-acetaminophen-related fulminant hepatic failure. Transplantation. 2005 ; 80: 930-6.
31. Sarasin FP, Majno PE, Llovet JM, Bruix J., Mentha G., Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology. 2001 ; 33: 1073-9.
32. Bravata DM, Olkin I., Barnato AE, Keeffe EB, Owens DK Health-related quality of life after liver transplantation: a meta-analysis. Liver Transpl Surg. 1999 ; 5: 318-31.
33. Shechter SM, Bryce CL, Alagoz O., et al. A clinically based discrete-event simulation of end-stage liver disease and the organ allocation process. Med Decis Making. 2005 ; 25: 199-209.
34. Neuberger J., Adams D., MacMaster P., Maidment A., Speed M. Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. BMJ. 1998 ; 317: 172-5.
35. Jacoby LH For bioethics-the role of empirical research. Am J Bioeth. 2006 ; 6: 58-9.
36. Baron J. A decision analysis of consent. Am J Bioeth. 2006 ; 6: 46-52.
37. Stahl JE, Kong N., Shechter SM, Schaefer AJ, Roberts MS A methodological framework for optimally reorganizing liver transplant regions. Med Decis Making. 2005 ; 25: 35-46.
38. Ratcliffe J., Buxton M. Patients' preferences regarding the process and outcomes of life-saving technology: an application of conjoint analysis to liver transplantation. Int J Technol Assess Health Care. 1999 ; 15: 340-51.
39. Geddes CC, Rodger RS, Smith C., Ganai A. Allocation of deceased donor kidneys for transplantation: opinions of patients with CKD. Am J Kidney Dis. 2005 ; 46: 949-56.
40. Ratcliffe J., Buxton M., Young T., Longworth L. Determining priority for liver transplantation: a comparison of cost per QALY and discrete choice experiment-generated public preferences. Appl Health Econ Health Policy. 2005 ; 4: 249-55.
41. Jacob M., Lewsey JD, Sharpin C., Gimson A., Rela M., van der Meulen JH Systematic review and validation of prognostic models in liver transplantation. Liver Transpl. 2005 ; 11: 814-25.